1616 Eastlake Avenue East
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
CEO: Michael Sistenich
CMO: Dr. Colleen Delaney
CFO: Darren Scotti
Vice President, Manufacturing: Jason Carstens
Director of Program Management: Heather Brammer
Please click here for Nohla's job opportunities.
Please click here for Nohla's science.